Grifols in 7.5 million euros HIV research agreement

11 April 2018

Spanish drugmaker Grifols (GRF: MC) has announced a new collaboration agreement with IrsiCaixa AIDS Research Institute.

Grifols will finance current and future research lines to advance the search for new treatments for HIV/AIDS and associated diseases, such as infectious, oncological, neurodegenerative and age-related conditions.

The accord will also enable IrsiCaixa to address other critical challenges in the biomedical field, including the study of the human microbiome and emerging infectious diseases, and leverage its accumulated knowledge on HIV/AIDS and resultant immune disorder.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK